{"disease":{"id":"still-s-disease","name":"Still's disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"kineret","indication_name":"Still's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anakinra","generic_name":"Kineret","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist","quality_score":41,"revenue":null,"mechanism":""},{"drug_id":"tocilizumab","indication_name":"Still's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"anakinra","indication_name":"Still's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kineret","generic_name":"ANAKINRA","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Kineret blocks the action of interleukin-1, a protein that promotes inflammation."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT05200715","title":"AutoInflammatory Disease Alliance Registry (AIDA)","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"University of Siena","has_results":false},{"nct_id":"NCT03510442","title":"Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","has_results":false},{"nct_id":"NCT07517250","title":"A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06497491","title":"An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT06405152","title":"Assessment of Macrophage Activation syndromE in STill's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT05239702","title":"Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT02204293","title":"Canakinumab for Treatment of Adult-onset Still's Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":true},{"nct_id":"NCT06992505","title":"Assessment of Macrophage Activation syndromE in STill's Disease in Italy","phase":"","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT05715736","title":"Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Syneos Health","has_results":false},{"nct_id":"NCT07203001","title":"A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07191444","title":"A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05814159","title":"A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT04717635","title":"Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03265132","title":"A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT04752371","title":"A Study to Evaluate Camoteskimab in Participants With Still's Disease","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Apollo Therapeutics Ltd","has_results":false},{"nct_id":"NCT07151157","title":"Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3,"lead_sponsor_name":"Ruijin Hospital","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}